POLISCOPE
Back to feed
Part ofbiotechnology →
HR3029FEDERALin_committee
High Impact

HR 3029 requires nucleic acid screening for synthetic DNA orders to improve biosecurity

Original title: To amend the Research and Development, Competition, and Innovation Act to support nucleic acid screening, and for other purposes.

July 21, 2026

biotechnologynational securityresearch and developmentfederal legislation

Track this bill to get notified when it advances a stage. One tap to stop, anytime.

Where This Stands

Introduced
Committee
Floor Vote
Passed
Signed

Currently in_committee. The next step in the legislative lifecycle is Floor Vote.

Last action
Received in the Senate and Read twice and referred to the Committee on Commerce, Science, and Transportation.Jul 21, 2026

Version history

Only one version on file - nothing to compare yet. As later stages (committee substitute, engrossed, enrolled) are captured, the redline appears here.

View official text →

The Frame

What this does

This measure creates a new federal regulatory framework for the synthetic biology industry, directly impacting how biotech firms and research laboratories procure genetic materials to mitigate the risk of biological threats.

Who is mentioned in the record

Potentially affected actors named in the source documents. Mention is not a position.

Synthetic DNA providers

These companies must implement new screening protocols for all customer orders.

Biotechnology research laboratories

These entities will be subject to new vetting and screening requirements when ordering synthetic genetic materials.

What changed

Current stage: in_committee.

What's next

Floor Vote.

Summary

HR 3029 mandates that companies providing synthetic sequences implement screening protocols to prevent the synthesis of dangerous s. This bill amends the Research and Development, Competition, and Innovation Act to establish federal standards for identifying and vetting customers who order .

Key Facts

You don't have to trust us. Each fact below is taken straight from the official document - click any one to see the exact passage, highlighted in the original.

Why It Matters

This measure creates a new federal regulatory framework for the synthetic biology industry, directly impacting how biotech firms and research laboratories procure genetic materials to mitigate the risk of biological threats.

Frequently Asked Questions

What is nucleic acid screening?
It is a process used by providers to check the genetic sequences requested by customers against databases of known dangerous s to ensure they are not being used for harmful purposes.
Who does this bill affect?
It primarily affects companies that synthesize and sell DNA sequences, as well as the research laboratories and biotech firms that purchase these materials.

News Coverage

No news coverage found yet. Articles are indexed twice daily.

Discoveries

Patterns POLISCOPE noticed across the record. These are observations to investigate, not conclusions.

policy shift80% confidence

Federalization of Biosecurity Screening

The bill represents a shift toward mandatory federal oversight of private synthetic DNA synthesis, moving beyond voluntary industry standards.

Research and Development, Competition, and Innovation Act

Connected Entities

organizationCommittee on Commerce, Science, and Transportation“The Senate committee currently reviewing the bill.”Map →
otherResearch and Development, Competition, and Innovation Act“The existing law being amended by HR 3029.”Map →

Analysis Score

0–100
  • Significance75
    How much this matters to a regular citizen
  • Controversy40
    Intensity of disagreement among stakeholders
  • Entertainment10
    Compellingness for a non-policy-wonk reader
  • Buzz30
    Current news / social attention level

Publisher tools

Share or embed this record

POLISCOPE publisher tools

Share or embed this record